{
    "root": "301eda8e-2ce2-ad99-e063-6294a90a1b19",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valacyclovir Hydrochloride",
    "value": "20250312",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC"
        }
    ],
    "indications": "Valacyclovir tablets are a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1–infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1–infected patients.",
    "contraindications": "Valacyclovir tablets may be given without regard to meals.\n                     Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500-mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate\n  \n   [see\n   \n    Dosage and Administration (2.3)]\n  \n   .",
    "warningsAndPrecautions": "Valacyclovir Tablets, USP are available containing 556.2 mg or 1.112 grams of valacyclovir hydrochloride, USP (hydrous), which are equivalent to 500 mg or 1 gram of valacyclovir, on the anhydrous basis, respectively.\n                  The 500 mg tablets are white, film-coated, oval, unscored tablets with\n \n  M122imprinted with black ink on one side of the tablet and plain on the other side of the tablet. They are available as follows:\n\n \n                  NDC 0378-4275-93 \n    bottles of 30 tablets\n \n                  NDC 0378-4275-77 \n    bottles of 90 tablets\n \n                  The 1 gram tablets are white, film-coated, oval tablets with a partial break line on both sides of the tablet and \n \n  M123 imprinted with black ink on one side of the tablet. They are available as follows:\n\n \n                  NDC 0378-4276-93 \n    bottles of 30 tablets\n \n                  NDC 0378-4276-77 \n    bottles of 90 tablets\n \n                  \n                     Storage: Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.",
    "adverseReactions": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation\n \n  [see\n  \n   Adverse Reactions (6.3)]\n \n  ."
}